Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) shares dropped 0.8% during trading on Monday . The stock traded as low as $2.35 and last traded at $2.44. Approximately 93,912 shares were traded during trading, a decline of 84% from the average daily volume of 578,072 shares. The stock had previously closed at $2.46.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Co-Diagnostics to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings downgraded Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $67.50.
View Our Latest Analysis on Co-Diagnostics
Co-Diagnostics Stock Down 2.5%
Co-Diagnostics (NASDAQ:CODX – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($4.06) EPS for the quarter, missing the consensus estimate of ($3.75) by ($0.31). The firm had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.13 million. Co-Diagnostics had a negative net margin of 6,760.63% and a negative return on equity of 164.92%.
Institutional Investors Weigh In On Co-Diagnostics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC increased its stake in shares of Co-Diagnostics by 393.8% in the 3rd quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock valued at $44,000 after purchasing an additional 100,901 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Co-Diagnostics by 314.1% during the 2nd quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock worth $47,000 after buying an additional 126,105 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Co-Diagnostics by 40.4% during the 4th quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock worth $81,000 after buying an additional 129,158 shares during the last quarter. 14.99% of the stock is currently owned by institutional investors.
About Co-Diagnostics
Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.
Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.
Featured Articles
- Five stocks we like better than Co-Diagnostics
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
